The global genome editing market size was valued at USD 6.39 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 17.8% from 2023 to 2030. Over the past few years, the market expansion has mostly been driven by growing synthetic gene demand and increasing CRISPR genome editing technology implementation in various biotechnology fields. Additionally, the growth is anticipated to be fueled by rising government funding, an increase in the production of genetically modified crops, and an increase in the number of genomics projects. The growth is also driven by CRISPR-based diagnostic tools which have helped in COVID-19 diagnostics. For instance, a group of academics from Nanyang Technological University created the VaNGuard (Variant Nucleotide Guard) diagnostic test in March 2021. The ability of this test to identify SARS-CoV-2 strains with mutations will increase the use of CRISPR genome editing technology in the diagnostics industry.
In addition, ongoing technological developments in gene-editing technologies play a significant role in the market's ability to generate profits. For instance, in April 2021, Retron Library Recombineering (RLR) was created by scientists at Harvard's Wyss Institute for Biologically Inspired Engineering. This new gene-editing tool made it possible to run millions of genetic experiments at once and thus increase editing rates.
The growth of the market is fueled by favorable government regulations related to synthetic biology, increasing demand for engineered genes and cells, and rising investments from the government and large companies. The invention and implementation of various unconventional gene editing methods for editing purposes is another significant advancement in gene therapy and molecular biology that has contributed to the market's growth.
Additionally, the accessibility of user-friendly gene therapy systems, the advancement of genome engineering, and the potential for gene therapy to facilitate quick genome-wide analyses of gene function are all contributing to the market growth during the forecast period.
The CRISPR/Cas9 segment dominated the market and accounted for the largest revenue share of 42.9% in 2022. This method can accurately divide DNA strands and insert new genetic information, making it a useful tool in gene therapy, medication development, and scientific research. CRISPR/Cas9 is a popular alternative for genome editing because of its simplicity, high efficiency, and precision, and it is suitable for a range of applications.
The clinical applications of CRISPR have been widely accepted. This is evident from the growing number of ongoing clinical trials using gene-editing techniques for the treatment of a wide range of diseases such as AIDS, cancer, and genetic diseases. In addition to human health, this technology is witnessing increasing usage in agriculture and animal breeding applications.
Furthermore, the market for TALENs is expected to grow dramatically in the coming years. The TALENs technology's DNA-binding protein may be created to recognize specific DNA sequences, allowing for precise gene editing. There are several uses for this method, including gene therapy, agricultural improvement, and disease models.
The limitations of CRISPR technology have increased in applications of the TALEN technique in some hard-to-edit genomic regions. According to a study published in January 2021, TALEN is found to be a more suitable tool for compact DNA studies. Such studies would increase the adoption of the TALEN technique in research settings in the coming years.
The ex-vivo delivery method segment generated the highest revenue of USD 3.36 billion in 2022 and is estimated to grow at a CAGR of around 14.3% from 2023 to 2030. This can be attributed to the advantages offered by this mode type such as simplicity of control in DNA modification. The rising clinical trial pipeline that deploys genome processing tools has spurred the ex-vivo delivery segment growth with the increased usage of this delivery method.
As a result of the human genome project (HGP) success, almost 7,000 new human genetic diseases have been discovered. While ex vivo gene editing-based gene therapies like CAR-T have had a significant impact Further, most patients with genetic diseases require in vivo treatments, which necessitate clinically accurate editing tools, and safe and targeted delivery systems that can be scaled to assist the entire patient population, this factor contributing to the growth of the segments.
On the other hand, the in-vivo segment is expected to emerge as the most lucrative segment over the study period. However, focused efforts are being taken to overcome the challenges with growing clinical trials focused on easy target tissues using in-vivo delivery.
The genetic engineering segment held the highest revenue share of 68.8% in 2022. The dominant share is due to the rapidly growing field of gene and stem cell therapy. The usage of CRISPR gene editing in human induced pluripotent stem cells (hiPSCs) related programs has important implications in stem cell research for the treatment of various diseases.
Cell line engineering, which has several applications in biotechnology, gene therapy, and drug development, is used in several research initiatives. It involves manipulating the genetic material in cells to produce or change an organism's features, and it can potentially transform medicine.
The market for cell line engineering is expected to grow rapidly in the near future due to advancements in technology and the increased need for personalized medicine. The clinical application segment dominated the market and accounted for a significant revenue share in 2022.
Additionally, the efficiency of CHO cell lines is being improved through the widespread application of CRISPR technology. Large-molecule medicines are frequently produced using these cell lines. As a result of the CRISPR tool's application, the biopharmaceutical industry is advancing, fueling the market for genome editing. In addition to genetic engineering, genome editing technologies offer significant growth potential in medical fields like diagnostics and drug development.
The efficacy and safety of UCART123, for instance, are being assessed in patients with R/R acute myeloid leukemia as part of a clinical investigation funded by Cellectis S.A. Based on TALEN gene-editing technology. The use of genome editing in medication discovery and development is anticipated to expand significantly in the upcoming years due to the rising need for innovative, potent treatments for a variety of disorders. New medications that target genes or gene pathways can be created through genome editing, which could result in more effective and specialized treatments for diseases.
The contract segment dominated the market with a share of 64.0% in 2022. This can be attributed to the high extent of outsourcing activities in the gene editing space driven by the lower costs and greater flexibility in operations offered by such activities as compared to in-house development. The segment is expected to witness further growth due to the increasing capabilities offered by key entities in this domain. For instance, in December 2022, a CRO company named Crown Bioscience, Inc, collaborated with ERS Genomics Limited to gain access to ERS’s CRISPR/Cas9 patent portfolio and strengthen its market presence in the gene editing space. Such initiatives are expected to boost the outsourcing opportunities in the genome editing domain and can positively affect the market growth.
The in-house segment is expected to grow at a CAGR of 13.4% from 2023 to 2030 owing to the advantages offered by in-house operations such as ownership of supply channels, enhanced process troubleshooting abilities, as well as the potential for future in-house scale-up activities that can prove to be beneficial in the long run. As a result, companies such as Precision BioSciences hold in-house cGMP compliant manufacturing facilities that produce genome-edited products, such as allogeneic CAR T cell therapies. These factors are anticipated to drive the revenue growth for the segment over the forecast period.
The biotechnology and pharmaceutical companies segment dominated the market and accounted for the major revenue share of 51.2% in 2022. The presence of a growing number of research activities for novel therapeutic development is the major factor contributing to revenue generation. Moreover, global pharmaceutical companies are collaborating with emerging companies to develop novel technologies. Increased research development efforts for novel treatments are the main factor fueling revenue growth.
Additionally, an increase in strategic developments by key market players is anticipated to fuel market expansion. For instance, to create innovative gene treatments employing the CRISPR/Cas9 technology for treating various diseases, CRISPR Therapeutics AG and Capsida Biotherapeutics Inc. formed a strategic agreement in January 2022. According to the agreement, Capsida will donate its adeno-associated virus (AAV) delivery technology, while CRISPR Therapeutics will contribute its expertise in genome editing.
The academic and research institutions segment is expected to grow at a CAGR of 20.1% during 2023-2030. This is due to the increasing usage of technology on college campuses. Many organizations are developing lessons for high school and college students to help students understand gene editing functions.
For instance, in January 2022, the ChristianaCare Gene Editing Institute visited high schools and colleges with its ground-breaking CRISP in Box Educational Toolkit to promote awareness of one of the most potent biomedical technologies that are steadily approaching the point where it will alter the way diseases are treated. This existing kit cannot be used to alter live things due to it only containing safe, artificial elements. Instead, it could be used to demonstrate how CRISPR operates.
North America dominated the global market with a share of 47.9% in 2022. Owing to the growing investments in the R&D of gene editing technologies. Due to the presence of several biotechnology and pharmaceutical companies working on developing genome editing technologies, the region is projected to maintain its dominance over the projected period.
Further, with increased government funding and support for scientific R&D, the U.S. held the largest market share for genome editing technology in North America. The presence of major players such as Editas Pharmaceuticals, Thermo Fisher Scientific, and CRISPR Therapeutics is also anticipated to fuel market expansion in this region, as is the increasing investment in genomic research.
The Asia Pacific region is anticipated to register the maximum growth at a CAGR of 19.6% from 2023 to 2030. Owing to the government programs promoting the advancement of genomic research, China is the largest market for genome editing technology in the Asia Pacific region.
The region's genome editing market is ready for growth due to the Chinese government's increasing focus on precision medicine and the presence of major players such as BGI and Hebei Senlang Biotechnology. In addition, increasing investment in R&D, a rise in the prevalence of genetic diseases, and government initiatives that support genomic research are all projected to boost the global market for genome editing to significant growth in the coming years.
Most players are undertaking licensing agreements with technology developers to enhance their market presence. Key players are engaged in strategic initiatives such as acquisitions, partnerships, and collaborations to help maximize their market share. For instance, in April 2022,Thermo Fisher Scientific launched a new Gibco CTS TrueCut Cas9 Protein, as a high-quality support material and documents are essential as researchers that use the genome editing techniques go from basic research to therapeutic settings. It is a promising option for CAR T-cell therapies study using CRISPR-Cas9 genome editing as it consistently provides higher than 90% efficacy in human primary T-cells and high editing effectiveness in all examined cell lines.
In the past few years, numerous research programs have initiated using CRISPR-based gene editing for finding out viable treatment options for chronic diseases. In May 2023, one such research program was being conducted at the Lewis Katz School of Medicine at the University of Nebraska Medical Center published that they have successfully treated HIV infection in animals. The program used CRISPR to deactivate CCR5 and excise HIV-1 DNA fragments from infected cells. With such developments, the demand for genome editing is likely to grow. Some prominent players in the global genome editing market include:
Cibus, Recombinetics, Inc.
Intellia Therapeutics, Inc.
Caribou Biosciences, Inc.
Takara Bio USA
Horizon Discovery Group plc
Integrated DNA Technologies, Inc.
New England Biolabs
OriGene Technologies, Inc.
Thermo Fisher Scientific, Inc.
Market size value in 2023
USD 7.95 billion
Revenue forecast in 2030
USD 24.99 billion
CAGR of 17.8% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Technology, delivery method, application, mode, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Merck KGaA; Cibus; Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript; New England Biolabs; OriGene Technologies, Inc.; Lonza; Thermo Fisher Scientific, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global genome editing market report based on technology, delivery method, application, mode, end-use, and region:
Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Delivery Method Outlook (Revenue, USD billion, 2018 - 2030)
Mode Outlook (Revenue, USD Billion, 2018 - 2030)
End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations
Application Outlook (Revenue, USD Billion, 2018 - 2030)
Cell Line Engineering
Animal Genetic Engineering
Plant Genetic Engineering
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East & Africa
b. The global genome editing market size was estimated at USD 6.39 billion in 2022 and is expected to reach USD 7.95 billion in 2023.
b. The global genome editing market is expected to grow at a compound annual growth rate of 17.8% from 2023 to 2030 to reach USD 24.99 billion by 2030.
b. North America dominated the genome editing market with a share of 47.91% in 2022. The presence of strong research, as well as a commercial base for advanced therapy development coupled with a high number of clinical trials being conducted for gene and stem cell therapies in the region, has majorly contributed to the dominance of the region in the global market.
b. Some key players operating in the genome editing market include Merck KGaA; Cibus, Recombinetics, Inc.; Sangamo; Editas Medicine; Precision Biosciences; CRISPR Therapeutics; Intellia Therapeutics, Inc.; Caribou Biosciences, Inc.; Cellectis S.A.; AstraZeneca; Takara Bio USA; Horizon Discovery Group plc; Integrated DNA Technologies, Inc.; Egenesis Inc.; GenScript
b. Key factors that are driving the genome editing market growth include success in pre-clinical models drives demands for genome editing therapeutics, rising competition amongst market participants for business development, easy editing solutions for the development of therapeutics for a broad range of diseases, increasing demand for synthetic genes and genetically modified organisms, technological advancements in gene-editing technologies, and rising adoption in agricultural biotechnology.
b. The CRISPR/Cas9 segment dominated the market for genome editing and accounted for the largest revenue share of 42.9% in 2022.
b. The ex-vivo delivery method segment dominated the genome editing market and held the largest revenue share of 52.6% in 2022.
b. The developments in gene editing systems have revolutionized the genetic engineering space, with the cell line engineering application segment accounting for the largest revenue share of 68.8% in 2022.
b. The biotechnology and pharmaceutical companies segment dominated the genome editing market and accounted for the largest revenue share of 51.2% in 2022.
b. The contract-based genome editing mode segment dominated the market, accounting for the largest revenue share of 64.0% in 2022.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for COVID-19. The report will account for COVID-19 as a key market contributor.